ES2194911T3 - Metodo para evitar la agregacion de proteinas/peptidos cuando tiene lugar su rehidratacion o descongelacion. - Google Patents

Metodo para evitar la agregacion de proteinas/peptidos cuando tiene lugar su rehidratacion o descongelacion.

Info

Publication number
ES2194911T3
ES2194911T3 ES95921031T ES95921031T ES2194911T3 ES 2194911 T3 ES2194911 T3 ES 2194911T3 ES 95921031 T ES95921031 T ES 95921031T ES 95921031 T ES95921031 T ES 95921031T ES 2194911 T3 ES2194911 T3 ES 2194911T3
Authority
ES
Spain
Prior art keywords
rehydration
defrosting
avoiding protein
aggregation
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95921031T
Other languages
English (en)
Inventor
Bruce Joseph Roser
Camilo Colaco
Jaap Kampinga
Christopher Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Drug Delivery Ltd
Original Assignee
Elan Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22958303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2194911(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd
Application granted granted Critical
Publication of ES2194911T3 publication Critical patent/ES2194911T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE MUESTRAN METODOS PARA REDUCIR O PREVENIR LA AGREGACION DE UNA AMPLIA VARIEDAD DE SUSTANCIAS (P.E. COLOIDES, GLOBULOS ROJOS, MEDICAMENTOS) DURANTE LA CONGELACION/DESCONGELACION O DEHIDRATACION/REHIDRATACION EN LOS CUALES SE AÑADE TREHALOSA A UNA SOLUCION O SUSPENSION DE LA SUSTANCIA ANTES DE LA CONGELACION O DEHIDRATACION.
ES95921031T 1994-06-02 1995-06-02 Metodo para evitar la agregacion de proteinas/peptidos cuando tiene lugar su rehidratacion o descongelacion. Expired - Lifetime ES2194911T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25296794A 1994-06-02 1994-06-02

Publications (1)

Publication Number Publication Date
ES2194911T3 true ES2194911T3 (es) 2003-12-01

Family

ID=22958303

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95921031T Expired - Lifetime ES2194911T3 (es) 1994-06-02 1995-06-02 Metodo para evitar la agregacion de proteinas/peptidos cuando tiene lugar su rehidratacion o descongelacion.

Country Status (10)

Country Link
US (2) US6890512B2 (es)
EP (1) EP0762897B1 (es)
JP (2) JP4142095B2 (es)
CN (1) CN1188171C (es)
AT (1) ATE235919T1 (es)
DE (1) DE69530196T2 (es)
DK (1) DK0762897T3 (es)
ES (1) ES2194911T3 (es)
PT (1) PT762897E (es)
WO (1) WO1995033488A1 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5621094A (en) * 1990-05-14 1997-04-15 Quadrant Holdings Cambridge Limited Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
EP0762897B1 (en) * 1994-06-02 2003-04-02 Elan Drug Delivery Limited Method of preventing aggregation of proteins/peptides upon rehydration or thawing
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
CZ88697A3 (en) 1994-09-22 1997-09-17 Quadrant Holdings Cambridge Composition used for re-hydration and nourishment in the course of athletic outputs and processes for preparing thereof
US6964771B1 (en) * 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US6558901B1 (en) 1997-05-02 2003-05-06 Biomerieux Vitek Nucleic acid assays
IL124275A (en) 1997-05-02 2002-03-10 Bio Merieux Vitek Inc A method to produce sequences of nucleic acids
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
PT2193809E (pt) 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
FR2791895B1 (fr) * 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
MXPA04005865A (es) 2001-12-19 2004-09-13 Nektar Therapeutics Suministro de aminoglucosidos a los pulmones.
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
AU2003218308B2 (en) * 2002-03-20 2006-07-20 Advanced Inhalation Research, Inc. hGH (human growth hormone) formulations for pulmonary administration
US20050163725A1 (en) * 2002-03-20 2005-07-28 Blizzard Charles D. Method for administration of growth hormone via pulmonary delivery
US20070059761A1 (en) * 2003-05-13 2007-03-15 Bambad Cynthia C Storage and use of colloids
BRPI0415531B8 (pt) 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
WO2007038926A1 (en) * 2005-10-04 2007-04-12 Alk-Abelló A/S Solid vaccine formulation
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
WO2008118691A2 (en) 2007-03-22 2008-10-02 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US8974827B2 (en) * 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
RU2010104042A (ru) * 2007-07-09 2011-08-20 Новартис АГ (CH) Сохранение вторичной структуры пептида
WO2009010842A2 (en) * 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
CA2695178C (en) 2007-07-31 2015-06-23 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
US20090081785A1 (en) 2007-09-24 2009-03-26 Hememics Biotechnologies, Inc. Desiccated Biologics And Methods Of Preparing The Same
US20090090022A1 (en) * 2007-10-09 2009-04-09 Hememics Biotechnologies, Inc. Desiccation Chamber and Methods for Drying Biological Materials
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
JP4563476B2 (ja) 2008-07-09 2010-10-13 パナソニック株式会社 符号化器、復号化器及び符号化方法
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
WO2010054238A1 (en) 2008-11-07 2010-05-14 Baxter International Inc. Factor viii formulations
US9827205B2 (en) * 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
WO2011003820A1 (de) * 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Hitze- und schüttelstabile insulinzubereitungen
US9943075B2 (en) 2010-02-17 2018-04-17 Hememics Biotechnologies, Inc. Preservation solutions for biologics and methods related thereto
JP5341059B2 (ja) * 2010-11-09 2013-11-13 株式会社大塚製薬工場 幹細胞懸濁液
CA2895515C (en) 2010-12-09 2020-03-24 Niten V. Lalpuria Apparatus and method using dissolution additive to facilitate sample mixing and analysis
CN103781491A (zh) 2011-05-17 2014-05-07 索利吉尼克斯公司 热稳定性疫苗组合物及其制备方法
US9089529B2 (en) 2011-10-25 2015-07-28 Prothena Therapeutics Limited Antibody formulations and methods
US20150044251A1 (en) * 2011-12-23 2015-02-12 Novartis Ag Stable compositions for immunising against staphylococcus aureus
JP5432322B2 (ja) * 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
SG11201408262XA (en) * 2012-06-25 2015-01-29 Emergent Product Dev Gaithersburg Inc Temperature stable vaccine formulations
WO2015100344A1 (en) 2013-12-27 2015-07-02 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
WO2016069173A2 (en) * 2014-09-29 2016-05-06 Cook General Biotechnology Llc Uses of trehalose in cell suspensions
AU2017241626B2 (en) * 2016-03-28 2022-03-31 Gallant Pet, Inc. Viable cell compositions, and methods related to same
CN107373662B (zh) * 2017-07-07 2020-12-22 江西清源汉本生物科技有限公司 速溶金银花提取物及其制备方法
CN107307422B (zh) * 2017-07-07 2018-09-18 许辉良 速溶石斛提取物及其制备方法
CN107373663B (zh) * 2017-07-07 2020-12-25 江西清源汉本生物科技有限公司 速溶菊花提取物及其制备方法
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥方法
US20200325020A1 (en) * 2017-10-25 2020-10-15 Merck Sharp & Dohme Corp. Adjuvanted vaccines
US11604026B2 (en) 2019-03-14 2023-03-14 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557717A (en) 1968-05-17 1971-01-26 Gen Mills Inc Process for making candy floss
US3619294A (en) 1968-07-15 1971-11-09 Penick & Ford Ltd Method of combining crystalline sugar with impregnating agents and products produced thereby
US3632357A (en) 1969-07-29 1972-01-04 Standard Brands Inc Method of producing hard candy
US3655442A (en) 1969-08-27 1972-04-11 California & Hawaiian Sugar Method of making sugar and sugar products
US4127502A (en) 1977-06-10 1978-11-28 Eastman Kodak Company Stabilizers for reconstituted, lyophilized samples
DE2748132A1 (de) 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4158544A (en) 1978-07-17 1979-06-19 Beckman Instruments, Inc. Process for preparing a biological composition for use as a reference control in diagnostic analysis
US4588744A (en) 1978-09-19 1986-05-13 Mchugh John E Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide
US4327076A (en) 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4327077A (en) 1981-05-29 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4883762A (en) 1983-06-06 1989-11-28 Ciba Corning Diagnostics Corp. Stabilized isoenzyme control products
US4865871A (en) 1983-08-23 1989-09-12 Board Of Regents The University Of Texas System Method for cryopreparing biological tissue
DE3445010A1 (de) 1984-12-10 1986-06-19 Boehringer Mannheim Gmbh Kontroll- bzw. eichserum fuer die lipid-diagnostik
JPH0779694B2 (ja) 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
US4762857A (en) 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
GB8715238D0 (en) * 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
GB8801338D0 (en) 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
CA1331133C (en) 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5262296A (en) * 1988-03-30 1993-11-16 Toray Industries, Inc. Freeze-dried composition containing enzyme-labeled anti-human interferon-β antibody and enzyme immunoassay kit containing the composition
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
GB8917470D0 (en) 1989-07-31 1989-09-13 Quadrant Bioresources Ltd Composition and method
EP0542914A4 (en) 1990-08-10 1993-11-18 Analytical Control Systems, Inc. Improved diagnostic and therapeutic compositions
US5200399A (en) 1990-09-14 1993-04-06 Boyce Thompson Institute For Plant Research, Inc. Method of protecting biological materials from destructive reactions in the dry state
US5242792A (en) * 1991-02-25 1993-09-07 The United States Of America As Represented By The Secretary Of The Navy Method for the preservation of red blood cells by lyophilization using glycerol or inositol with disaccharides
US5422384A (en) 1992-11-25 1995-06-06 Battelle Memorial Institute Glass/polymer composites and methods of making
DE69428707T2 (de) 1993-08-20 2002-07-11 Nippon Shinyaku Co., Ltd. Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
EP0762897B1 (en) 1994-06-02 2003-04-02 Elan Drug Delivery Limited Method of preventing aggregation of proteins/peptides upon rehydration or thawing
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
BR9609188A (pt) 1995-06-07 1999-05-11 Quadrant Holdings Cambridge Métodos para incorporar substâncias de modo estável dentro de matrizes de vidro espumado secas e composições obtidas desse modo

Also Published As

Publication number Publication date
ATE235919T1 (de) 2003-04-15
JP4142095B2 (ja) 2008-08-27
US6890512B2 (en) 2005-05-10
JP2008179636A (ja) 2008-08-07
CN1156967A (zh) 1997-08-13
DK0762897T3 (da) 2003-07-21
US20050163750A1 (en) 2005-07-28
JPH10500990A (ja) 1998-01-27
WO1995033488A1 (en) 1995-12-14
US20010055583A1 (en) 2001-12-27
EP0762897B1 (en) 2003-04-02
DE69530196T2 (de) 2003-11-20
DE69530196D1 (de) 2003-05-08
PT762897E (pt) 2003-07-31
CN1188171C (zh) 2005-02-09
EP0762897A1 (en) 1997-03-19

Similar Documents

Publication Publication Date Title
ES2194911T3 (es) Metodo para evitar la agregacion de proteinas/peptidos cuando tiene lugar su rehidratacion o descongelacion.
DE19882492T1 (de) Verbesserter Kaskadenkühlungsprozess zur Verflüssigung von Erdgas
DOP1979002953A (es) Procedimiento para la purificacion de proteinas y producto obtenido.
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
NO884840L (no) Fremgangsmaate for behandling av underjordiske formasjonermed gelfluider som gir forsinket kryssbinding.
WO1994012637A3 (en) Novel human amyloid protein precursor homologue and kunitz-type inhibitors
NZ332954A (en) Use of BPI protein products to treat humans with hemorrhage due to trauma
ID24502A (id) Benda-benda, metode dan komposisi-komposisi untuk membersihkan hasil bumi dan protein hewani yang dapat dimakan
NO993424D0 (no) Fremgangsmåte til selektiv nedbrytning av melkeprotein i naervaer av andre melkeproteiner
ATE270305T1 (de) Peptide des antisekretorischen faktors, welches krankhafte permeabilitätsanderungen reguliert
NO885013D0 (no) FremgangsmŸte for fremstilling av bionedbrytbare mikrokapsler av vannopplelige peptider og proteiner, samt mikroka psler oppnŸdd ved fremgangsmŸten.
ATE245042T1 (de) Osmotisches verabreichungssystem und methode zur leistungserhöhung und verbesserung der initialwirkung von osmotischen verabreichungssystemen
ATE356878T1 (de) Herstellung von proteinen in eiern
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
HUP0001550A2 (hu) Fagyasztott élelmiszertermék
WO1999037782A3 (en) Frozen food product
ES2042461T1 (es) Producto y procedimiento para el te\ido oxidativo del cabello.
DE69013458D1 (de) Plasmide und Wirtszellen zur Expression von INA Protein (Ice nucleating protein).
EP0142059A3 (en) Method of heat-treating plasma proteins
ES2168282T3 (es) D-hidantoinasa recombinante, procedimiento para su preparacion y utilizacion.
ATE222704T1 (de) Herstellung von gefrorenen süsswaren
MX22991A (es) Agente edulcorante derivado del acido l-aspartico o l-glutamico y el procedimiento para su preparacion.
DE69509066D1 (de) Verzögerungssystem zur reduktion der geschwindigkeit von bewegenden objekten
ES2149331T3 (es) Fraccion de germen de algarroba con alto contenido en proteinas.
SE9604439D0 (sv) New receptor